This is the authors' abstract. We don't add key points for this paper.
IgM-selective proteolytic cleavage can become a groundbreaking tool for immunoassay-based bioanalysis. We tested the utility of a newly introduced IgM-selective protease in three different bioanalytical applications and showed that protease treatment can eliminate rheumatoid factor interference and simplify IgM isotyping. Surprisingly, we discovered that a gene therapy-induced immune response was underestimated in an anti-capsid IgG assay when treatment-emergent IgM were present in the matrix. Selective IgM digestion eliminated this interference.
No takes yet. Share an insight, caveat, or question.
Pöhler et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: